A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Erlotinib (Primary) ; Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 12 Apr 2018 Primary endpoint of progression-free survival has been met, according to results published in the Cancer.
- 12 Apr 2018 Results published in the Cancer
- 30 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.